Fizzah A Choudry1, Stephen M Hamshere1, Krishnaraj S Rathod1, Mohammed M Akhtar1, R Andrew Archbold2, Oliver P Guttmann1, Simon Woldman1, Ajay K Jain1, Charles J Knight1, Andreas Baumbach1, Anthony Mathur1, Daniel A Jones3. 1. Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. 2. Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom. 3. Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. Electronic address: dan.jones8@nhs.net.
Abstract
BACKGROUND: Coronavirus disease-2019 (COVID-19) is thought to predispose patients to thrombotic disease. To date there are few reports of ST-segment elevation myocardial infarction (STEMI) caused by type 1 myocardial infarction in patients with COVID-19. OBJECTIVES: The aim of this study was to describe the demographic, angiographic, and procedural characteristics alongside clinical outcomes of consecutive cases of COVID-19-positive patients with STEMI compared with COVID-19-negative patients. METHODS: This was a single-center, observational study of 115 consecutive patients admitted with confirmed STEMI treated with primary percutaneous coronary intervention at Barts Heart Centre between March 1, 2020, and May 20, 2020. RESULTS: Patients with STEMI presenting with concurrent COVID-19 infection had higher levels of troponin T and lower lymphocyte count, but elevated D-dimer and C-reactive protein. There were significantly higher rates of multivessel thrombosis, stent thrombosis, higher modified thrombus grade post first device with consequently higher use of glycoprotein IIb/IIIa inhibitors and thrombus aspiration. Myocardial blush grade and left ventricular function were significantly lower in patients with COVID-19 with STEMI. Higher doses of heparin to achieve therapeutic activated clotting times were also noted. Importantly, patients with STEMI presenting with COVID-19 infection had a longer in-patient admission and higher rates of intensive care admission. CONCLUSIONS: In patients presenting with STEMI and concurrent COVID-19 infection, there is a strong signal toward higher thrombus burden and poorer outcomes. This supports the need for establishing COVID-19 status in all STEMI cases. Further work is required to understand the mechanism of increased thrombosis and the benefit of aggressive antithrombotic therapy in selected cases.
BACKGROUND:Coronavirus disease-2019 (COVID-19) is thought to predispose patients to thrombotic disease. To date there are few reports of ST-segment elevation myocardial infarction (STEMI) caused by type 1 myocardial infarction in patients with COVID-19. OBJECTIVES: The aim of this study was to describe the demographic, angiographic, and procedural characteristics alongside clinical outcomes of consecutive cases of COVID-19-positive patients with STEMI compared with COVID-19-negative patients. METHODS: This was a single-center, observational study of 115 consecutive patients admitted with confirmed STEMI treated with primary percutaneous coronary intervention at Barts Heart Centre between March 1, 2020, and May 20, 2020. RESULTS:Patients with STEMI presenting with concurrent COVID-19infection had higher levels of troponin T and lower lymphocyte count, but elevated D-dimer and C-reactive protein. There were significantly higher rates of multivessel thrombosis, stent thrombosis, higher modified thrombus grade post first device with consequently higher use of glycoprotein IIb/IIIa inhibitors and thrombus aspiration. Myocardial blush grade and left ventricular function were significantly lower in patients with COVID-19 with STEMI. Higher doses of heparin to achieve therapeutic activated clotting times were also noted. Importantly, patients with STEMI presenting with COVID-19infection had a longer in-patient admission and higher rates of intensive care admission. CONCLUSIONS: In patients presenting with STEMI and concurrent COVID-19infection, there is a strong signal toward higher thrombus burden and poorer outcomes. This supports the need for establishing COVID-19 status in all STEMI cases. Further work is required to understand the mechanism of increased thrombosis and the benefit of aggressive antithrombotic therapy in selected cases.
Authors: Miguel A Alvarez Villela; Ahmad Alkhalil; Michael A Weinreich; Jonathan Koslowsky; Shunsuke Aoi; M Azeem Latib Journal: Tex Heart Inst J Date: 2021-11-01
Authors: Marwan Saad; Kevin F Kennedy; Hafiz Imran; David W Louis; Ernie Shippey; Athena Poppas; Kenneth E Wood; J Dawn Abbott; Herbert D Aronow Journal: JAMA Date: 2021-11-16 Impact factor: 56.272
Authors: Thomas A Kite; Peter F Ludman; Chris P Gale; Jianhua Wu; Adriano Caixeta; Jacques Mansourati; Manel Sabate; Pilar Jimenez-Quevedo; Luciano Candilio; Parham Sadeghipour; Angel M Iniesta; Stephen P Hoole; Nick Palmer; Albert Ariza-Solé; Alim Namitokov; Hector H Escutia-Cuevas; Flavien Vincent; Otilia Tica; Mzee Ngunga; Imad Meray; Andrew Morrow; Md Minhaj Arefin; Steven Lindsay; Ghada Kazamel; Vinoda Sharma; Aly Saad; Gianfranco Sinagra; Federico Ariel Sanchez; Marek Roik; Stefano Savonitto; Marija Vavlukis; Shankar Sangaraju; Iqbal S Malik; Sharon Kean; Nick Curzen; Colin Berry; Gregg W Stone; Bernard J Gersh; Anthony H Gershlick Journal: J Am Coll Cardiol Date: 2021-05-25 Impact factor: 24.094
Authors: Alexandre Abizaid; Carlos M Campos; Patrícia O Guimarães; José de Ribamar Costa; Breno A A Falcão; Fernanda Mangione; Adriano Caixeta; Pedro A Lemos; Fabio S de Brito; Ricardo Cavalcante; Cristiano Guedes Bezerra; Leandro Cortes; Henrique B Ribeiro; Francis R de Souza; Natassja Huemer; Renata M do Val; Bruno Caramelli; Daniela Calderaro; Felipe G Lima; Ludhmila A Hajjar; Roxana Mehran; Roberto Kalil Filho Journal: Catheter Cardiovasc Interv Date: 2021-04-27 Impact factor: 2.585